LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug.
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
03
05
2022
revised:
24
10
2022
accepted:
25
10
2022
entrez:
14
11
2022
pubmed:
15
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Epithelial-mesenchymal transition (EMT) is a cellular mechanism used by cancer cells to acquire migratory and stemness properties. In this study, we show, through in vitro, in vivo, and 3D culture experiments, that the mitochondrial protein LACTB manifests tumor suppressor properties in ovarian cancer. We show that LACTB is significantly down-regulated in epithelial ovarian cancer cells and clinical tissues. Re-expression of LACTB negatively effects the growth of cancer cells but not of non-tumorigenic cells. Mechanistically, we show that LACTB leads to differentiation of ovarian cancer cells and loss of their stemness properties, which is achieved through the inhibition of the EMT program and the LACTB-dependent down-regulation of Snail2/Slug transcription factor. This study uncovers a novel role of LACTB in ovarian cancer and proposes new ways of counteracting the oncogenic EMT program in this model system.
Identifiants
pubmed: 36375842
pii: 6/1/e202201510
doi: 10.26508/lsa.202201510
pmc: PMC9664245
pii:
doi:
Substances chimiques
beta-Lactamases
EC 3.5.2.6
LACTB protein, human
EC 3.4.-
Membrane Proteins
0
Mitochondrial Proteins
0
Snail Family Transcription Factors
0
SNAI2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 Cutano et al.
Références
Mol Cancer. 2011 Nov 10;10:139
pubmed: 22074556
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Am J Transl Res. 2021 Feb 15;13(2):601-616
pubmed: 33594312
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
pubmed: 16493418
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
Dev Cell. 2008 Jun;14(6):818-29
pubmed: 18539112
J Ovarian Res. 2014 Jul 27;7:76
pubmed: 25296567
Reprod Sci. 2017 Feb;24(2):291-299
pubmed: 27368877
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Cells. 2022 May 20;11(10):
pubmed: 35626737
Am J Pathol. 2012 Mar;180(3):1159-1169
pubmed: 22222226
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Cancer Cell Int. 2017 Jan 5;17:8
pubmed: 28070170
Dev Cell. 2019 May 6;49(3):313-316
pubmed: 31063750
Int J Mol Sci. 2020 Sep 05;21(18):
pubmed: 32899449
Oncogene. 2010 Oct 21;29(42):5741-54
pubmed: 20697346
Front Oncol. 2012 Apr 10;2:33
pubmed: 22655269
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
BMC Cancer. 2012 Mar 19;12:91
pubmed: 22429801
Oncogene. 2017 Mar;36(11):1546-1558
pubmed: 27617576
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):18960-5
pubmed: 19858488
Diabetes. 2009 Jul;58(7):1518-25
pubmed: 19401427
Oncogene. 2021 May;40(21):3772-3773
pubmed: 33958725
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cancer Manag Res. 2020 Jun 30;12:5181-5200
pubmed: 32636680
Oncol Rep. 2012 Oct;28(4):1399-405
pubmed: 22859015
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
Nature. 2008 Mar 27;452(7186):429-35
pubmed: 18344982
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS Biol. 2022 Dec 19;20(12):e3001899
pubmed: 36534696
Cancer Res. 2008 Apr 1;68(7):2329-39
pubmed: 18381440
Int J Mol Sci. 2017 Jul 30;18(8):
pubmed: 28758950
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Nature. 2017 Mar 30;543(7647):681-686
pubmed: 28329758
Cancer Lett. 2021 May 28;506:67-82
pubmed: 33675985
Am J Transl Res. 2018 Dec 15;10(12):4152-4162
pubmed: 30662658
J Obstet Gynaecol Can. 2014 Feb;36(2):133-140
pubmed: 24518912
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
Mol Cancer. 2014 Feb 24;13:37
pubmed: 24565133
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213009
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Oncogene. 2010 Feb 25;29(8):1103-13
pubmed: 19935705
Nat Genet. 2005 Jul;37(7):710-7
pubmed: 15965475
Cancer Cell Int. 2014 Sep 09;14(1):72
pubmed: 25278811
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
J Cell Sci. 2003 Feb 1;116(Pt 3):499-511
pubmed: 12508111
Cancer Res. 2021 Sep 15;81(18):4652-4667
pubmed: 34183354
Gynecol Oncol. 2005 Apr;97(1):155-65
pubmed: 15790452
BMC Evol Biol. 2008 Jan 28;8:26
pubmed: 18226203
Oncol Res. 2019 Mar 29;27(4):423-429
pubmed: 28835318
Exp Ther Med. 2022 Mar;23(3):247
pubmed: 35222724